Frank Buono, PhD
Research Scientist in PsychiatryCards
About
Research
Publications
2024
The Road to Reintegration: Evaluating the Effectiveness of VA Healthcare in Vocational Rehabilitation and Employment Retention for Veterans with Mental Health and Substance Use Disorders
Sprong M, Hollender H, Blankenberger B, Rumrill S, Lee Y, Bland T, Bailey J, Weber K, Gilbert J, Kriz K, Buono F. The Road to Reintegration: Evaluating the Effectiveness of VA Healthcare in Vocational Rehabilitation and Employment Retention for Veterans with Mental Health and Substance Use Disorders. Substance Abuse And Rehabilitation 2024, 15: 107-123. PMID: 39081876, PMCID: PMC11287469, DOI: 10.2147/sar.s462882.Peer-Reviewed Original ResearchMental health treatmentSubstance use disorder treatmentVeterans Integrated Service NetworkVocational rehabilitation servicesVocational rehabilitation programVocational rehabilitationSubstance use disordersMental healthHealth treatmentProgram enrollmentRehabilitation servicesRehabilitation programVA healthcareVA healthcare systemSubstance use disorder treatment servicesProgram evaluation dataFace significant barriersProgram evaluation designMultivariate logistic regression analysisHealth outcomesLogistic regression analysisIntegrated services networksVeteran patientsHealthcare systemPost-dischargeVirtual Reality in Medical Education
Buono F, Marks A, Lee D. Virtual Reality in Medical Education. Cyberpsychology Behavior And Social Networking 2024, 27: 361-362. PMID: 38841871, DOI: 10.1089/cyber.2024.27599.geditorial.Peer-Reviewed Original ResearchAntipsychotic agents in anxiety disorders: An umbrella review
Garakani A, Buono F, Salehi M, Funaro M, Klimowicz A, Sharma H, Faria C, Larkin K, Freire R. Antipsychotic agents in anxiety disorders: An umbrella review. Acta Psychiatrica Scandinavica 2024, 149: 295-312. PMID: 38382649, DOI: 10.1111/acps.13669.Peer-Reviewed Original ResearchSecond-generation antipsychoticsFirst-generation antipsychoticsGeneralized anxiety disorderStudies of antipsychoticsAnxiety disordersAntipsychotic agentsEfficacy of first-generation antipsychoticsTreatment of anxiety disordersEfficacy of antipsychotic agentsMeta-analysesAntidepressant treatmentNonantipsychotic medicationsAntipsychoticsFirst-line treatmentAnxietyComparing monotherapyUmbrella reviewDisordersQuetiapineSystematic reviewSide effectsAMSTAR-2Off-labelAPA PsycInfoCINAHL CompleteUnderstanding chronic pain in Neurofibromatosis Type 1 using the Neurofibromatosis Pain Module (NFPM)
Buono F, Larkin K, Zempsky W, Grau L, Martin S. Understanding chronic pain in Neurofibromatosis Type 1 using the Neurofibromatosis Pain Module (NFPM). American Journal Of Medical Genetics Part A 2024, 194: e63541. PMID: 38234177, DOI: 10.1002/ajmg.a.63541.Peer-Reviewed Original ResearchNeurofibromatosis type 1Chronic painImpact of CPPain modulationPain regionsModerate pain severityType 1Autosomal dominant genetic disorderCross-sectional studyQuality of lifeDominant genetic disorderMedical providersPain severitySensitive clinical measureDaily functioningClinical measuresPainEffective treatmentGenetic disordersNeurofibromatosisClinical assessmentMultiple domainsAdultsQuantitative responseProviders
2023
Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials
Merker V, Thompson H, Wolters P, Buono F, Hingtgen C, Rosser T, Barton B, Barnett C, Smith T, Haberkamp D, McManus M, Baldwin A, Moss I, Röhl C, Martin S. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials. Clinical Trials 2023, 21: 6-17. PMID: 38140900, PMCID: PMC10922038, DOI: 10.1177/17407745231205577.Peer-Reviewed Original ResearchPatient-reported outcome measuresClinical trialsOutcome measuresNeurofibromatosis 1Cutaneous neurofibromasDistress ScaleOlder adultsFinal consensus recommendationsKey secondary outcomesPatient-reported outcomesPatient-reported changesAppearance concernsSystematic literature searchNontumor manifestationsTreatment sequelaeSecondary outcomesBACKGROUND/Consensus recommendationsPatient's perspectiveTumor volumePatient representativesGood psychometric propertiesOutcome ratingsLiterature searchPlexiformWork readiness and barriers to employment during COVID-19 for individuals with Neurofibromatosis Type 1 (NF1)
Buono F, Polonsky M, Marks A, Larkin K, Sprong M. Work readiness and barriers to employment during COVID-19 for individuals with Neurofibromatosis Type 1 (NF1). Work 2023, 76: 1265-1273. PMID: 37355921, DOI: 10.3233/wor-220259.Peer-Reviewed Original ResearchFeasibility of a remotely monitored blood alcohol concentration device to facilitate treatment motivation
Buono F, Polonsky M, Sprong M, Aviles A, Cutter C. Feasibility of a remotely monitored blood alcohol concentration device to facilitate treatment motivation. Drug And Alcohol Dependence Reports 2023, 9: 100202. PMID: 38045492, PMCID: PMC10690544, DOI: 10.1016/j.dadr.2023.100202.Peer-Reviewed Original ResearchDisparities in program enrollment and employment outcomes for veterans with psychiatric and co-occurring substance use disorders referred or enrolled for VHA vocational rehabilitation
Sprong M, Hollender H, Lee Y, Williams L, Sneed Z, Garakani A, Buono F. Disparities in program enrollment and employment outcomes for veterans with psychiatric and co-occurring substance use disorders referred or enrolled for VHA vocational rehabilitation. Frontiers In Psychiatry 2023, 14: 1200450. PMID: 37520235, PMCID: PMC10382058, DOI: 10.3389/fpsyt.2023.1200450.Peer-Reviewed Original ResearchActive alcohol use disorderSubstance use disordersUse disordersVeterans Health Administration medical centersCo-occurring substance use disordersVocational rehabilitationProgram enrollmentCo-occurring alcoholCo-occurring depressionDiagnosis of anxietyCo-occurring diagnosesAlcohol use disorderPost-traumatic stress disorderInstitutional review boardVeteran patientsMedical CenterPsychiatric diagnosisCurrent studyBipolar disorderRehabilitation servicesReview boardStress disorderEffective interventionsAnxiety diagnosesDiagnosisMaintaining Engagement in Adults with Neurofibromatosis Type 1 to Use the iCanCope Mobile Application (iCanCope-NF)
Buono F, Larkin K, Pham Q, De Sousa D, Zempsky W, Lalloo C, Stinson J. Maintaining Engagement in Adults with Neurofibromatosis Type 1 to Use the iCanCope Mobile Application (iCanCope-NF). Cancers 2023, 15: 3213. PMID: 37370823, PMCID: PMC10296339, DOI: 10.3390/cancers15123213.Peer-Reviewed Original ResearchPsychosocial treatmentsContingency managementSemi-structured interviewsChronic painGoal settingEngagement dataParticipants' experiencesCurrent studyNeurofibromatosis type 1EngagementCustomized mobile applicationConsistent issueAdultsMixed methodologyPositive feedbackMixed methodsExperienceMoodPhysical activityMobile applicationsGoalPain treatmentSleepSubset of dataIndividualsImpact of Substance Use Disorders on Employment for Veterans
Sprong ME, Hollender H, Paul E, Gilbert J, Weber K, Garakani A, Buono FD. Impact of Substance Use Disorders on Employment for Veterans. Psychological Services 2023, 20: 222-231. PMID: 35849362, DOI: 10.1037/ser0000690.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disordersImpact of SUDMental health conditionsSerious mental health conditionsVocational rehabilitation programCommunity-based employmentMedical conditionsRehabilitation programAlcohol useHealth conditionsVeteransIllicit drugsVR programClosure statusDisordersPresent studyFindingsTransitional work
News & Links
News
- August 07, 2024
Grant to Help Team Develop Dynamic 3D Tumor Analysis
- June 21, 2024Source: Cyberpsychology, Behavior, and Social Networking
Buono, Marks Guest Edit Special Issue of 'Cyberpsychology, Behavior and Social Networking'
- May 21, 2024
Garakani, Buono Awarded Grant from AAPL Institute for Education and Research
- April 26, 2024
Buono, Cortes-Briones, Lee Honored with 2024 Blavatnik Awards